Đang chuẩn bị liên kết để tải về tài liệu:
Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: A phase I study

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Anti-programmed cell death receptor-1 (PD-1) monotherapy is the standard treatment for metastatic melanoma in current. Camrelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody whose safety and efficacy have not been reported in advanced Asian melanoma patients. |

TÀI LIỆU LIÊN QUAN

Ebook Child safety coloring & activity book

Antimicrobial activity and safety evaluation of Enterococcus faecium KQ 2.6 isolated from peacock feces

Ebook The microbiological safety of low water activity foods and spices

Contribution of production and loss terms of fission products on incontainment activity under severe accident condition for VVER-1000

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

Influence of age and level of activity on the applicability of a walker orthosis - a prospective study in different cohorts of healthy volunteers

SAFETY AUDIT/ INSPECTION MANUAL: A Publication of the American Chemical Society Committee on Chemical Safety

Ebook Food, nutrition and wellness: Part 1

Ebook Glencoe food, nutrition and wellness: Part 2

Báo cáo y học: "Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus"